NCT04339426 is a Phase 2 clinical trial of Atovaquone/Azithromycin in Covid19, sponsored by HonorHealth Research Institute.

Who is sponsoring NCT04339426?

NCT04339426 is sponsored by HonorHealth Research Institute.

What drugs are being tested in NCT04339426?

Interventions in NCT04339426: Atovaquone/Azithromycin.

Is NCT04339426 still recruiting?

NCT04339426 is currently terminated. Last updated 4 March 2022.

Last reviewed 2022-03-04 · How we verify

NCT04339426

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

Terminated Phase 2 Last updated 4 March 2022

What this trial tests

Phase 2 trial testing Atovaquone/Azithromycin in Covid19 in 3 participants. Terminated before completion.

Timeline

20 April 2020

Primary endpoint
11 February 2022

11 February 2022

Quick facts

Lead sponsor	HonorHealth Research Institute
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	20 April 2020
Primary completion	11 February 2022
Estimated completion	11 February 2022
Sites	1 location across United States

Drugs / interventions tested

Atovaquone/Azithromycin — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

HonorHealth Research Institute

Who can join

Adults 18 to 95, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate anti-malarial/anti-infective single-agent and in combination for patients with confirmed COVID-19 infection. The first combination to be evaluated is atovaquone and azithromycin.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, et al · · 2020 · cited 246× · PMID 32687918 · DOI 10.1016/j.lfs.2020.118102
COVID-19: Characteristics and Therapeutics.
Chilamakuri R, Agarwal S. · · 2021 · cited 192× · PMID 33494237 · DOI 10.3390/cells10020206
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Viral Respiratory Pathogens and Lung Injury.
Clementi N, Ghosh S, De Santis M, Castelli M, et al · · 2021 · cited 127× · PMID 33789928 · DOI 10.1128/cmr.00103-20
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2020 · cited 105× · PMID 32717568 · DOI 10.1016/j.drup.2020.100719
Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.
Pandey A, Nikam AN, Shreya AB, Mutalik SP, et al · · 2020 · cited 80× · PMID 32497632 · DOI 10.1016/j.lfs.2020.117883
Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
Pani A, Lauriola M, Romandini A, Scaglione F. · · 2020 · cited 73× · PMID 32534189 · DOI 10.1016/j.ijantimicag.2020.106053
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other HonorHealth Research Institute trials

Trials by the same sponsor.

NCT05229588 — Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations · Phase 2 · completed
NCT05216120 — Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas · Phase 2 · withdrawn
NCT05004025 — Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma · Phase 1 · completed
NCT04611139 — Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers · Phase 1 · withdrawn
NCT05175521 — Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04339426 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by HonorHealth Research Institute
Last refreshed: 4 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04339426.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing